MEDICAL CANNABIS IN PEDIATRICS (MYTH OR REAL POSSIBILITY)
Keywords:
cannabinoids, medical marijuana, pediatrics.Abstract
The public interest in cannabis for medical use is acknowledged, and anecdotal reports of effectiveness in individual patients are compelling. Our objective is to make overview of the current scientific papers for medicinal cannabis use in pediatrics population.
Literature review was conducted utilizing, PubMed, Medline, and Google Scholar. Cannabis based product have promising potential for add-on treatment of certain conditions in pediatrics. Well-designed Randomized Clinical Trials (RCTs) with sufficient number of patients are imperative to demonstrate benefit of therapeutic use. In pediatrics, the greatest evidence for medicinal cannabis use is for seizure disorders. RCTs have demonstrated the safety and efficacy of oral Cannabidiol (CBD) for treatment of seizures associated with Lennox-Gastaut or Dravet syndrome.
References
Ali S, Scheffer IE, Sadleir LG (2019). Efficacy of cannabinoids in pediatric epilepsy. Dev Med Child Neurol, 61: 13-18
Ananth P, Reed-Weston A, Wolfe J. (2018) Medical marijuana in pediatric oncology: A review of the evidence and implications for practice. Pediatr Blood Cancer: 65(2).
Ananth P, Ma C, Al-Sayegh H, et al. (2018). Provider Perspectives on Use of Medical Marijuana in Children With Cancer. Pediatrics, 141(1)
Campbell, C. T., Phillips, M. S., & Manasco, K. (2017). Cannabinoids in pediatrics. The journal of pediatric pharmacology and therapeutics: JPPT 22(3), 176–185.
Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. EurNeuropsychopharmacol. 27(8): 795-808.
Dan B. (2015). Cannabinoids in paediatric neurology. Dev Med Child Neurol, 57:984
Devinsky O, Cross JH, Laux L, et al. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 25; 376(21): 2011-2020.
Devinsky O, Marsh E, Friedman DT, et al. (2016). Cannabidiol in patients with treatment-resistent epilepsy: an open label interventional trial. Lancet Neurol; 15: 270-8.
Devinsky O, Patel AD, Cross JH, et al. (2018). Effect of Cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med:378: 1888-97.
Devinsky O, Patel AD, Thiele EA, et al. (2018). Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology: 90(14), e1204–e1211.
Fernández-López D, Lizasoain I, Moro MA, Martínez-Orgado J. (2013). Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain sciences, 3(3), 1043–1059.
Fisher T, Golan H, Schiby G, et al. (2016). In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Current oncology: 23(2), S15–S22.
Grotenhermen F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. ClinPharmacokinet; 42: 327– 60
Hadland SE, Knight JR, Harris SK. (2015). Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. J DevBehavPediatr.; 36(2): 115-23.
Halbmeijer N, GroenewegM. De Ridder L. (2019). Cannabis, a potential treatment option in pediatric IBD? Still a long way to go, Expert Review of Clinical Pharmacology, 12:4, 355-361.
Hausman-Kedem., M, Menascu., S, Kramer U. (2018). Efficacy of CBDenriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain Dev.; 40(7): 544-551.
Hess EJ, Moody KA, Geffrey AL, et al. (2016). Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia: 57: 1617-1624.
Huntsman RJ, Tang-Wai R, Alcorn J, et al. (2019). Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study. Frontiers in neurology: 10, 716.
Hussain SA, Zhou R, Jacobson C, et al. (2015). Perceived efficasy of cannabidiolenriched cannabis extracts for treatment of pediatric epilepsy. A potential role for infantile spasma and Lennox-Gastaut syndrome. Epilepsy Behav: 47: 138-41.
IbeasBihC, Chen T, Nunn AV, et al. (2015). Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics; 12: 699–730.
Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, et al. (2019). Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Systematic Reviews 8:1.
Jones NA, Hill AJ, Smith I, et al. (2010). Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J PharmacolExpTher; 332: 569– 77.
Klotz KA, Schulze-Bonhage A, Antonio-Arce VS, Jacobs J. (2018). Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey. Frontiers in neurology, 9, 731.
Lattanzi S, Brigo F, Trinka E, Zaccara G, et al. (2018). Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 78(17): 1791-1804.
Lattanzi S, TrinkaE, RussoE, et al. (2019). Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Drugs Today; 55(3): 177-196
Libzon S, Schleider LB, Saban N, et al. 2018). Medical cannabis for pediatric moderate to severe complex motor disorders. J Child Neurol. 33(9): 565-571
Loeffen E, Kremer L, D. van de Wetering M, et al. (2018). Reducing pain in children with cancer: Methodology for the development of a clinical practice guideline. Pediatr Blood Cancer.66:e27698.
O’Connell BK, Gloss D, Devinsky O. (2017). Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 70(Pt B): 341-348.
Polito S, MacDonald T, Romanick M, et al. (2018). Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. Pediatr Blood cancer; 65:e27374.
Press CA, Knupp KG, Chapman KE. (2015). Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav; 45: 49– 52.
Reithmeier, D., Tang-Wai, R., Seifert, B., et al. (2018). The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study. BMC pediatrics, 18(1).
Russo EB. (2017). Cannabis and epilepsy: An ancient treatment returns to the fore. Epilepsy Behav; 70 (Pt B): 292–7.
S. Rod Rassekh. (2019). Urgent need for “EBMM” in pediatric oncology: Evidence based medical marijuana. Pediatric Hematology and Oncology, 1-2.
Splinter W (2019). Novel Approaches for Treating Pain in Children. CurrOncol Rep. 4; 21(2): 11.
Szaflarski JP, Bebin EM, ComiA. et al. (2018). Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia, 59(8), 1540–1548.
Thiele EA, Marsh ED, French JA, et al (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet; 391: 1085–96.
Tzadok M, Uliel-Siboni, Linder I, et al. (2016). CBD- enriched cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure; 35: 41-4.
